The Top Reasons Pharmaceutical Companies are Switching to Oral Thin Films September 22, 2020 - Baystreet.ca Most parents give the wrong dose of liquid medication, says The New York Times. In some cases, twice as much as instructed. In a study published in the journal, Pediatrics, it randomly assigned 2,110 parents to one of five pairings of the many possible combinations of tools and label instructions. “In nine trials, 84.4 percent of the parents made at least one dosing error, and more than 68 percent of the errors were overdoses. About 21 percent of parents at least once measured out more than twice the proper dose. Smaller doses produced more errors. When the dose was 2.5 milliliters, there were more than four times as many errors as when it was 5 milliliters.” It’s why “many pharmaceutical companies are switching their products from tablets to fast dissolving oral thin films,” says the National Library of Medicine. “Films have all the advantages of tablets (precise dosage, easy administration) and those of liquid dosage forms (easy swallowing, rapid bioavailability). Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages forms.” With that, some of the top companies to watch on such news include XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF), GW Pharmaceuticals (NASDAQ:GWPH), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and Cure Pharmaceutical Holding Corp. (OTC:CURR). XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF) BREAKING NEWS: XPhyto Therapeutics Corp., a next-generation bioscience company, is pleased to announce an update on its oral disintegrating film drug delivery programs. XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH, is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients cannabidiol and tetrahydrocannabinol. The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medicines for the treatment of severe childhood forms of Epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. THC based medicines have been approved for the treatment of nausea associated with cancer chemotherapy and for the treatment of anorexia associated with weight loss in AIDS patients. The registered formulation for CBD is a lipophilic solution in sesame oil and for THC it is a soft gelatin capsule filled with THC in a sesame oil carrier. XPhyto is developing ODF dosage forms for CBD and THC based on Vektor’s ODF platform. The dosage forms are designed to increase API bioavailability using Vektor’s rapid release technology. Increased product efficacy and patient convenience is expected through anticipated faster onset of drug action, more predictable therapeutic activity and ease of use. In addition, research organizations will have an opportunity to work with a reliable and reproducible dosage form to study THC and CBD activity and develop innovative treatment regimes. Cannabinoid ODF dosage forms are also expected to yield reduced costs per daily prescription versus oil-based systems due to the use of significantly less API per daily dosage. Initial dissolution data for XPhyto’s sublingual CBD product, first announced December 6, 2019, indicates an at least 5-fold increase in API bioavailability over oil-based delivery methods. A European human bioavailability study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021. XPhyto anticipates initial dissolution data for its sublingual THC product to be available and announced in the coming weeks. Further to its current CBD ODF and THC ODF development programs, the Company has identified a 1:1 CBD/THC ODF product for the treatment of MS induced spasticity as a prospective candidate for future development. Additional cannabis ODF products are being investigated as potential future development initiatives. XPhyto is reviewing these opportunities with respect to R&D timelines and capacity, cost of development and market opportunities. The Company will announce progress on new ODF initiatives as they are advanced. The global thin film drug market is expected to grow to USD $29.2 billion by 2024 at a CAGR of 10.5% according to Market Data Forecast. The global cannabis market is forecast to grow to USD $63.5 billion by 2024 with a CAGR of 21.1%, with Germany set to lead industry growth with a CAGR of 76.8% into 2022 according to Arcview Market Research. Germany is a medical cannabis only market. Other related developments from around the markets include: GW Pharmaceuticals (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board. “I am very pleased to welcome David to our Board of Directors,” stated Dr. Geoffrey Guy, GW’s Founder and Chairman of the Board. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from David’s wealth of experience as we continue to grow commercially and advance our pipeline with the goal of bringing breakthrough medicines to patients with significant unmet needs.” Johnson & Johnson (NYSE:JNJ) announced that it is accepting applications for its 2021 Women in STEM2D (WiSTEM2D) Scholars Award, aimed at supporting assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design. For three years, each recipient will receive mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is Oct. 15, 2020 at 9 a.m. HST. Launched in June 2017, the Johnson & Johnson WiSTEM2D Scholars Award aspires to fuel development of female STEM2D leaders, and inspire career paths in STEM2D, by supporting the research of the awarded women in their respective STEM2D fields. Pfizer Inc. (NYSE:PFE) announced that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September 19-21, 2020. Data to be presented include findings from the Phase 3 CROWN study of LORBRENA® (lorlatinib)* in first-line ALK- positive non-small cell lung cancer (NSCLC), building on Pfizer’s extensive heritage in precision medicine research. In addition to the CROWN study, several biomarker analyses that provide further insights on Pfizer medicines across a range of cancers will be presented, including BAVENCIO® (avelumab), BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), and IBRANCE® (palbociclib). BAVENCIO is being developed and commercialized in collaboration with Merck KGaA, Darmstadt, Germany. Cure Pharmaceutical Holding Corp. (OTC:CURR) an innovative drug delivery and development company, today announced that it has entered into a Memorandum of Understanding to acquire 100% of privately held Sera Labs for total up-front consideration of $20 million, comprising $19 million in CURE stock at a valuation of $2.75 per share, and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. The transaction also includes the potential for an earn out of up to $20 million in CURE stock at a valuation of $3.34 per share within two years of the closing of the acquisition, contingent upon Sera Labs achieving certain key financial targets. The structure of the earn out is designed to align risk and reward between CURE stockholders and Sera Labs’ management, with a focus on strong operational alignment and financial execution. The transaction is expected to close, subject to a definitive agreement and customary closing conditions, by the fourth quarter of 2020. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for XPhyto Therapeutics Corp. by a third party. We own ZERO shares of XPhyto Therapeutics Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com
The Top Reasons Pharmaceutical Companies are Switching to Oral Thin Films September 22, 2020 - Baystreet.ca Most parents give the wrong dose of liquid medication, says The New York Times. In some cases, twice as much as instructed. In a study published in the journal, Pediatrics, it randomly assigned 2,110 parents to one of five pairings of the many possible combinations of tools and label instructions. “In nine trials, 84.4 percent of the parents made at least one dosing error, and more than 68 percent of the errors were overdoses. About 21 percent of parents at least once measured out more than twice the proper dose. Smaller doses produced more errors. When the dose was 2.5 milliliters, there were more than four times as many errors as when it was 5 milliliters.” It’s why “many pharmaceutical companies are switching their products from tablets to fast dissolving oral thin films,” says the National Library of Medicine. “Films have all the advantages of tablets (precise dosage, easy administration) and those of liquid dosage forms (easy swallowing, rapid bioavailability). Statistics have shown that four out of five patients prefer orally disintegrating dosage forms over conventional solid oral dosages forms.” With that, some of the top companies to watch on such news include XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF), GW Pharmaceuticals (NASDAQ:GWPH), Johnson & Johnson (NYSE:JNJ), Pfizer Inc. (NYSE:PFE), and Cure Pharmaceutical Holding Corp. (OTC:CURR). XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF) BREAKING NEWS: XPhyto Therapeutics Corp., a next-generation bioscience company, is pleased to announce an update on its oral disintegrating film drug delivery programs. XPhyto’s wholly owned German subsidiary, Vektor Pharma TF GmbH, is currently advancing two sublingual ODF development programs for the delivery of the active pharmaceutical ingredients cannabidiol and tetrahydrocannabinol. The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medicines for the treatment of severe childhood forms of Epilepsy, specifically Dravet syndrome and Lennox-Gastaut syndrome. THC based medicines have been approved for the treatment of nausea associated with cancer chemotherapy and for the treatment of anorexia associated with weight loss in AIDS patients. The registered formulation for CBD is a lipophilic solution in sesame oil and for THC it is a soft gelatin capsule filled with THC in a sesame oil carrier. XPhyto is developing ODF dosage forms for CBD and THC based on Vektor’s ODF platform. The dosage forms are designed to increase API bioavailability using Vektor’s rapid release technology. Increased product efficacy and patient convenience is expected through anticipated faster onset of drug action, more predictable therapeutic activity and ease of use. In addition, research organizations will have an opportunity to work with a reliable and reproducible dosage form to study THC and CBD activity and develop innovative treatment regimes. Cannabinoid ODF dosage forms are also expected to yield reduced costs per daily prescription versus oil-based systems due to the use of significantly less API per daily dosage. Initial dissolution data for XPhyto’s sublingual CBD product, first announced December 6, 2019, indicates an at least 5-fold increase in API bioavailability over oil-based delivery methods. A European human bioavailability study for its sublingual CBD product is planned for Q1 2021 with results expected in Q2 2021. XPhyto anticipates initial dissolution data for its sublingual THC product to be available and announced in the coming weeks. Further to its current CBD ODF and THC ODF development programs, the Company has identified a 1:1 CBD/THC ODF product for the treatment of MS induced spasticity as a prospective candidate for future development. Additional cannabis ODF products are being investigated as potential future development initiatives. XPhyto is reviewing these opportunities with respect to R&D timelines and capacity, cost of development and market opportunities. The Company will announce progress on new ODF initiatives as they are advanced. The global thin film drug market is expected to grow to USD $29.2 billion by 2024 at a CAGR of 10.5% according to Market Data Forecast. The global cannabis market is forecast to grow to USD $63.5 billion by 2024 with a CAGR of 21.1%, with Germany set to lead industry growth with a CAGR of 76.8% into 2022 according to Arcview Market Research. Germany is a medical cannabis only market. Other related developments from around the markets include: GW Pharmaceuticals (NASDAQ:GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines today announced the appointment of David Gryska to the Board of Directors. Mr. Gryska will also serve as a member of the Audit Committee. Mr. Gryska brings valuable global pharmaceutical and biotechnology industry experience and executive-level financial leadership to GW’s Board. “I am very pleased to welcome David to our Board of Directors,” stated Dr. Geoffrey Guy, GW’s Founder and Chairman of the Board. “As a highly regarded leader in the biopharmaceutical industry, we look forward to benefiting from David’s wealth of experience as we continue to grow commercially and advance our pipeline with the goal of bringing breakthrough medicines to patients with significant unmet needs.” Johnson & Johnson (NYSE:JNJ) announced that it is accepting applications for its 2021 Women in STEM2D (WiSTEM2D) Scholars Award, aimed at supporting assistant or associate academic professors in the disciplines of Science, Technology, Engineering, Math, Manufacturing and Design. For three years, each recipient will receive mentorship from leaders at Johnson & Johnson and a total $150,000 ($50,000 each year). The deadline for applications is Oct. 15, 2020 at 9 a.m. HST. Launched in June 2017, the Johnson & Johnson WiSTEM2D Scholars Award aspires to fuel development of female STEM2D leaders, and inspire career paths in STEM2D, by supporting the research of the awarded women in their respective STEM2D fields. Pfizer Inc. (NYSE:PFE) announced that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September 19-21, 2020. Data to be presented include findings from the Phase 3 CROWN study of LORBRENA® (lorlatinib)* in first-line ALK- positive non-small cell lung cancer (NSCLC), building on Pfizer’s extensive heritage in precision medicine research. In addition to the CROWN study, several biomarker analyses that provide further insights on Pfizer medicines across a range of cancers will be presented, including BAVENCIO® (avelumab), BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), and IBRANCE® (palbociclib). BAVENCIO is being developed and commercialized in collaboration with Merck KGaA, Darmstadt, Germany. Cure Pharmaceutical Holding Corp. (OTC:CURR) an innovative drug delivery and development company, today announced that it has entered into a Memorandum of Understanding to acquire 100% of privately held Sera Labs for total up-front consideration of $20 million, comprising $19 million in CURE stock at a valuation of $2.75 per share, and $1 million in cash, with an initial, additional commitment of $4 million for working capital in support of accelerating Sera Labs’ growth. The transaction also includes the potential for an earn out of up to $20 million in CURE stock at a valuation of $3.34 per share within two years of the closing of the acquisition, contingent upon Sera Labs achieving certain key financial targets. The structure of the earn out is designed to align risk and reward between CURE stockholders and Sera Labs’ management, with a focus on strong operational alignment and financial execution. The transaction is expected to close, subject to a definitive agreement and customary closing conditions, by the fourth quarter of 2020. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for XPhyto Therapeutics Corp. by a third party. We own ZERO shares of XPhyto Therapeutics Corp. Please click here for full disclaimer. Contact Information: 2818047972 ty@LifeWaterMedia.com